Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003809 · ClinicalTrials.gov registry record · Phase 3
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00003809: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00003809 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003809, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether cisplatin plus monoclonal antibody therapy is more effective than cisplatin alone for metastatic or recurrent head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of cisplatin with or without monoclonal antibody in treating patients who have metastatic or recurrent head and neck cancer.
Interventions
- DRUG cisplatin
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08-06 |
| Phase | Phase 3 |
What the finished NCT00003809 record still lists
NCT00003809 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00003809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003809 about?
NCT00003809 is a clinical study titled "Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether cisplatin ...
What is the current status of trial NCT00003809?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-08-06.
What interventions are being tested in trial NCT00003809?
The interventions under investigation include: cisplatin (DRUG), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003809?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI